Lack of correlation of the progression free survival and CD133 mRNA levels may be compounded by a number of factors including lack of clear imaging parameters in 2003 as CHOI criteria was later introduced to address frequent discrepancies of CT scan imaging in interpreting tumor response and progression in patients with GIST tumors treated with imatinib [18]. Here, PROM1 is linked to gastrointestinal stromal tumor.